CJC-1295 (no DAC) + Ipamorelin quick reference
What is CJC-1295 (no DAC) + Ipamorelin?
Two peptides that both push the pituitary to release growth hormone.
People use the blend for sleep, recovery and body composition.
Not approved. The blend has never been tested in a human trial.
How CJC-1295 (no DAC) + Ipamorelin works
Tells the pituitary to make and release growth hormone.
Triggers a separate GH release signal.
Ipamorelin left ACTH and cortisol alone in pigs.
No-DAC lacks the long-acting part; DAC form lasts 5.8-8.1 days.
What CJC-1295 (no DAC) + Ipamorelin is studied for
DAC form raised GH 2-10x and IGF-1 1.5-3x in healthy adults.
DAC form kept normal pulses and raised the low points.
Ipamorelin did not beat placebo: 25.3 vs 32.6 h to first meal.
CJC-1295 trial NCT00267527 was stopped early.
Ipamorelin released GH without extra cortisol in pigs.
Ipamorelin raised bone mineral content in female rats over 12 weeks.
CJC-1295 (no DAC) + Ipamorelin dosing protocol
| What was tested | Amount and schedule |
|---|---|
| Human dose of this blend | Not established |
| CJC-1295 WITH DAC (a different, long-acting form), healthy adults | 30 or 60 mcg per kg under the skin, single doses or 2-3 doses a week or two weeks apart (28- and 49-day trials) |
| Ipamorelin, healthy men | One 15-minute drip into a vein, from 4.21 up to 140.45 nmol per kg |
| Ipamorelin, after bowel surgery | 0.03 mg per kg into a vein, twice a day, up to 7 days |
Sources: Teichman 2006 (CJC-1295 with DAC), Gobburu 1999 and Beck 2014 / NCT00672074 (ipamorelin). CJC-1295 without DAC lacks the long-acting part, so these amounts should not be copied across.
Label and trial amounts come from the sources below. Community amounts are what people report; they have not been tested.
Mixing
Example only. Check the split per peptide on your vial.
What the research found
Healthy adults, placebo-controlled trials of 28 and 49 days using CJC-1295 WITH DAC (Teichman 2006). This is not the no-DAC form. Measured growth hormone (GH) and IGF-1 in blood:
Teichman SL et al. J Clin Endocrinol Metab 2006 (PMID 16352683); Gobburu JV et al. Pharm Res 1999 (PMID 10496658). In the one ipamorelin trial that looked at a health outcome (bowel recovery after surgery, 114 patients, NCT00672074), it did not beat placebo: median 25.3 vs 32.6 hours to first meal, p = 0.15 (Beck 2014, PMID 25331030).
CJC-1295 (no DAC) + Ipamorelin community experience
What users report. Not tested in trials.
Positive reports
- Better sleep Most common report, often within 1-2 weeks.
- Vivid dreams Often noticed early in a cycle.
- Easier recovery Some feel less sore after training.
- Slow body change Gradual shifts when diet and training stay steady.
Negative & mixed
- Injection welts Redness or welts at the site are common.
- Puffiness and flushing Mild water retention and facial puffiness recur.
- Sleep trouble Some wake often early in a cycle.
- Tingling and swelling Numbness or joint swelling is reported.
CJC-1295 (no DAC) + Ipamorelin stacking
The blend itself: two GH signals at once. Not studied together.
Less food and slower stomach emptying. Not studied together.
Different targets. Not studied together.
CJC-1295 (no DAC) + Ipamorelin side effects & safety
Common
- DAC-form trials: no serious reactions at 30-60 mcg/kg.
- Ipamorelin by vein: side effects 87.5% vs 94.8% on placebo.
- Injection-site redness or welts (community).
- Flushing and mild puffiness (community).
- Headache or hunger (community).
Less common
- FDA flags CJC-1295: faster heart rate, whole-body vasodilation.
- FDA cites a study with deaths after ipamorelin by vein.
- Numbness, tingling or joint swelling in user reports.
- HIV trial of CJC-1295 stopped early; cause not confirmed.
Precautions
- Not approved; FDA lists both on its compounding risk list.
- GH-raising drugs: tesamorelin label bars use with active cancer.
- GH and IGF-1 rise: watch glucose and swelling.
- Blend dose and long-term safety are unknown.
Our verdict on CJC-1295 (no DAC) + Ipamorelin
Popular pairing with a sound GH rationale, but no human trial of the blend. Dose and long-term safety are unknown.
CJC-1295 (no DAC) + Ipamorelin FAQ
Is CJC-1295 no DAC the same as with DAC?
No. DAC lasts days; no-DAC does not. Trial data are for the DAC form.
Is the blend approved?
No. I found no approved product for either peptide.
Has the blend been tested in people?
No. Each peptide has separate human data only.
Does ipamorelin raise cortisol?
Not in pigs (Raun 1998). Human data are limited.
Sources
- Teichman SL et al. J Clin Endocrinol Metab 2006 (CJC-1295 with DAC, healthy adults), PMID 16352683
- Ionescu M, Frohman LA. J Clin Endocrinol Metab 2006, PMID 17018654
- Gobburu JV et al. Pharm Res 1999 (ipamorelin PK/PD in volunteers), PMID 10496658
- Beck DE et al. Int J Colorectal Dis 2014 (ipamorelin, postoperative ileus), PMID 25331030, NCT00672074
- Raun K et al. Eur J Endocrinol 1998 (ipamorelin pharmacology), PMID 9849822
- ClinicalTrials.gov NCT00267527 (CJC-1295 in HIV visceral obesity, terminated)
- DailyMed search 2026-11: no listing for ipamorelin or CJC-1295
- Raun K et al. 1998 (pig data on ACTH and cortisol), PMID 9849822
- Johansen PA et al. J Endocrinol 2000 (ipamorelin, rat bone), PMID 10828840
- FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (content current 04/22/2026)